,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'destiny-04']
following the #asco22 meeting and the progress is palapable. destiny-04 trial in mbc (met with a standing ovation) and patient advocates presenting to a full house ( ) on #rwd in trials "a statistical difference is not the same as clincial benefit"
The next project of the International Cancer Genome Consortium; translating genomic knowledge to improve outcomes for people affected by cancer. #ThisIsICGCARGO